Therapy Areas: Vaccines
Bavarian Nordic receives order for 1.5 million smallpox/monkeypox vaccine doses
19 July 2022 -

Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday a further order in Europe for its smallpox/monkeypox vaccine.

An undisclosed European country has ordered an additional 1.5 million doses of IMVANEX, a non-replicating smallpox vaccine.

Deliveries are scheduled to start in the fourth quarter of 2022, but the majority of the doses will be delivered in 2023. This order therefore has no impact on the company's financial guidance for for this year.

Paul Chaplin, president and CEO of Bavarian Nordic, said in a statement: "While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts."